TRex Bio, Inc. (NASDAQ:TRXB) Stock Short Interest Report for October

TRex Bio, Inc. (NASDAQ:TRXB) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 195,608 shares. Based on an average trading volume of 183,613 shares, the days-to-cover ratio is presently 1.1 days.

Wall Street Analyst Weigh In

Separately, Wedbush assumed coverage on shares of TRex Bio in a report on Monday. They issued an “outperform” rating and a $30.00 price target for the company. One research analyst has rated the stock with a Buy rating. Based on data from MarketBeat, TRex Bio currently has an average rating of “Buy” and a consensus price target of $30.00.

TRex Bio Stock Performance

NASDAQ:TRXB opened at $13.74 on Monday. TRex Bio has a 52-week low of $13.10 and a 52-week high of $16.56.

Insider Buying and Selling

In other news, major shareholder Alexandria Venture Investments acquired 178,571 shares of TRex Bio stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the completion of the purchase, the insider owned 1,346,501 shares in the company, valued at approximately $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.